These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 11909785)

  • 1. Use of ramipril in preventing stroke: double blind randomised trial.
    Bosch J; Yusuf S; Pogue J; Sleight P; Lonn E; Rangoonwala B; Davies R; Ostergren J; Probstfield J;
    BMJ; 2002 Mar; 324(7339):699-702. PubMed ID: 11909785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial.
    Lonn E; Shaikholeslami R; Yi Q; Bosch J; Sullivan B; Tanser P; Magi A; Yusuf S
    J Am Coll Cardiol; 2004 Jun; 43(12):2200-6. PubMed ID: 15193680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramipril: a review of its use in the prevention of cardiovascular outcomes.
    Warner GT; Perry CM
    Drugs; 2002; 62(9):1381-405. PubMed ID: 12076194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
    Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
    Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).
    Marre M; Lievre M; Chatellier G; Mann JF; Passa P; Ménard J;
    BMJ; 2004 Feb; 328(7438):495. PubMed ID: 14960504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.
    Mathew J; Sleight P; Lonn E; Johnstone D; Pogue J; Yi Q; Bosch J; Sussex B; Probstfield J; Yusuf S;
    Circulation; 2001 Oct; 104(14):1615-21. PubMed ID: 11581138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on ramipril in the prevention of cardiovascular outcomes.
    Warner GT; Perry CM
    Am J Cardiovasc Drugs; 2003; 3(2):113-6. PubMed ID: 14727938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
    Lacourcière Y; Neutel JM; Davidai G; Koval S
    Am J Hypertens; 2006 Jan; 19(1):104-12. PubMed ID: 16461201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood-pressure reduction and cardiovascular risk in HOPE study.
    Sleight P; Yusuf S; Pogue J; Tsuyuki R; Diaz R; Probstfield J;
    Lancet; 2001 Dec 22-29; 358(9299):2130-1. PubMed ID: 11784631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing stroke with ramipril. Superiority of particular class of antihypertensive agent remains to be shown.
    Yudkin JS
    BMJ; 2002 Aug; 325(7361):439. PubMed ID: 12201280
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of ramipril on ambulatory blood pressure: a multicenter trial.
    Burris JF
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S131-3. PubMed ID: 1725022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.
    MacMahon S; Sharpe N; Gamble G; Clague A; Mhurchu CN; Clark T; Hart H; Scott J; White H
    J Am Coll Cardiol; 2000 Aug; 36(2):438-43. PubMed ID: 10933355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
    Lüders S; Schrader J; Berger J; Unger T; Zidek W; Böhm M; Middeke M; Motz W; Lübcke C; Gansz A; Brokamp L; Schmieder RE; Trenkwalder P; Haller H; Dominiak P;
    J Hypertens; 2008 Jul; 26(7):1487-96. PubMed ID: 18551027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.
    Sleight P; Redon J; Verdecchia P; Mancia G; Gao P; Fagard R; Schumacher H; Weber M; Böhm M; Williams B; Pogue J; Koon T; Yusuf S;
    J Hypertens; 2009 Jul; 27(7):1360-9. PubMed ID: 19506526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
    Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
    Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
    Trials; 2015 Dec; 16():581. PubMed ID: 26686682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
    Mallion JM; Omboni S; Barton J; Van Mieghem W; Narkiewicz K; Panzer PK; Puig JG; Stefanadis C; Zweiker R;
    Blood Press Suppl; 2011 Apr; 1():3-11. PubMed ID: 21091270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.